An increase signals potential overpayment for past acquisitions or a deterioration in the long-term outlook of acquired business units.
The non-cash charge recognized when the carrying amount of goodwill exceeds its implied fair value. This reflects a down...
Common across companies with active M&A strategies; peers often report this periodically during annual impairment testing.
goodwill_impairment| Segment | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
|---|---|---|---|---|---|---|---|---|
| Biopharma Laboratory Services | $83.40M | $83.40M | $83.40M | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Covance Drug Development | $83.40M | $83.40M | $83.40M | $83.40M | — | — | — | — |
| LabCorp Diagnostics | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total | — | — | — | — | — | — | — | — |
Biopharma Laboratory Services, LabCorp Diagnostics are derived from annual filings.
Biopharma Laboratory Services, Covance Drug Development, LabCorp Diagnostics were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.